Dramamine, Nix Drive Prestige Consumer Sales

Consumers’ OTC drug choices extend beyond pain relievers, heartburn remedies and allergy formulations, Prestige Consumer Healthcare points out as it announces reported revenues up 0.8% to $279.3m in its latest quarter.

Prestige Consumer highlights its advertising over the years for Dramamine: 2018 and 2020, top left to right, and 2021 and 2023, bottom. • Source: Source: Prestige Consumer Healthcare

Consumers’ OTC drug choices extend beyond pain relievers, heartburn remedies and allergy formulations, Prestige Consumer Healthcare points out by noting its Dramamine motion sickness and Nix lice treatment line as sales growth leaders in its latest quarter.

More from Archive

More from HBW Insight

End Of Year Recovery Ensures Recordati’s OTC Business Keeps Growing

 
• By 

Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.

State Actions, Proposals On Food Additive Bans Reflect Interest In Aligning With RFK Jr.’s View

 

Changes established in West Virginia and proposed in numerous other states gained momentum after Trump was elected to his second term as president and nominated Kennedy to head HHS.

CA Prop 65: Personal Care Firms Wrestle With Listing Of Common Stabilizer, Packaging Material

 

Personal care companies selling in California that suspect they are subject to its listing of a common stabilizer and packaging material should collect Certificates of Analysis for all raw materials, pursue third-party formula testing and retain counsel.